

Anti-WASF1 Antibody

Catalog # AP60651

Product Information

Application	WB, IHC, IF/IC
Primary Accession	Q92558
Reactivity	Human, Mouse, Rat, Bovine
Host	Rabbit
Clonality	Polyclonal
Calculated MW	61652

Additional Information

Gene ID	8936
Other Names	KIAA0269; SCAR1; WAVE1; Wiskott-Aldrich syndrome protein family member 1; WASP family protein member 1; Protein WAVE-1; Verprolin homology domain-containing protein 1
Target/Specificity	KLH-conjugated synthetic peptide encompassing a sequence within the center region of human WASF1. The exact sequence is proprietary.
Dilution	WB~~WB (1/500 - 1/1000), IHC (1/100 - 1/200), IF/IC (1/100 - 1/500) IHC~~WB (1/500 - 1/1000), IHC (1/100 - 1/200), IF/IC (1/100 - 1/500) IF/IC~~N/A
Format	Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide.
Storage	Store at -20 °C.Stable for 12 months from date of receipt

Protein Information


Name	WASF1 (HGNC:12732)
Synonyms	KIAA0269, SCAR1, WAVE1
Function	Downstream effector molecule involved in the transmission of signals from tyrosine kinase receptors and small GTPases to the actin cytoskeleton. Promotes formation of actin filaments. Part of the WAVE complex that regulates lamellipodia formation (PubMed: 29961568). The WAVE complex regulates actin filament reorganization via its interaction with the Arp2/3 complex (By similarity). As component of the WAVE1 complex, required for BDNF-NTRK2 endocytic trafficking and signaling from early endosomes (By similarity). Also involved in the regulation of mitochondrial dynamics (PubMed: 29961568).
Cellular Location	Cytoplasm, cytoskeleton. Synapse {ECO:0000250 UniProtKB:Q5BJU7} Cell

junction, focal adhesion. Note=Dot- like pattern in the cytoplasm. Concentrated in Rac-regulated membrane- ruffling areas (PubMed:9889097). Partial translocation to focal adhesion sites might be mediated by interaction with SORBS2 (PubMed:18559503). In neurons, colocalizes with activated NTRK2 after BDNF addition in endocytic sites through the association with TMEM108 (By similarity). {ECO:0000250 | UniProtKB:Q8R5H6, ECO:0000269 | PubMed:18559503, ECO:0000269 | PubMed:9889097}


Tissue Location

Highly expressed in brain. Lowly expressed in testis, ovary, colon, kidney, pancreas, thymus, small intestine and peripheral blood


Images



Western blot analysis of WASF1 expression in HEK293T (A), H1792 (B), mouse spleen (C), rat muscle (D), rat spleen (E) whole cell lysates. (Predicted band size: 61 kDa; Observed band size: 75 kDa)




Immunohistochemical analysis of WASF1 staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.



Immunofluorescent analysis of WASF1 staining in HeLa cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark. DAPI was used to stain the cell nuclei (blue).

Immunohistochemical analysis of WASF1 staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated



compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.